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Abstract. Epigenetic parameters such as DNA methylation 
and histone modifications play pivotal roles in carcinogenesis. 
Global histone modification patterns have been implicated 
as possible predictors of cancer recurrence and prognoses 
in a great variety of tumor entities. Our study was designed 
to evaluate the association among trimethylated histone H3 
at lysine 27 (H3K27me3), clinicopathological variables and 
outcome in early-stage non-small cell lung cancer (NSCLC). 
The expression of H3K27me3 and its methyl transferase, 
enhancer of zeste homolog 2 (EZH2) together with prolif-
erating cell nuclear antigen (PCNA) were evaluated by 
immunohistochemistry in normal lung tissue (n=5) and 
resected NSCLC patients (n=42). In addition, the specificity 
of antibody for H3K27me3 was tested by western blot 
analysis. The optimal cut-off point of H3K27me3 expression 
for prognosis was determined by the X-tile program. The 
prognostic significance was determined by means of Kaplan-
Meier survival estimates and log-rank tests. As a result, 
enhanced trimethylation of H3K27me3 was correlated with 
longer overall survival (OS) and better prognosis (P<0.05). 
Moreover, both univariate and multivariate analyses 
indicated that H3K27me3 level was a significant and inde-
pendent predictor of better survival (hazard ratio, 0.187; 95% 
confidence interval, 0.066-0.531, P=0.002). Furthermore, 
H3K27me3 expression was positively correlated with DNA 
methylation level at CCGG sites while reversely related to 
EZH2 expression (P<0.05). In conclusion, H3K27me3 level 
defines unrecognized subgroups of NSCLC patients with 
distinct epigenetic phenotype and clinical outcome, and can 
probably be used as a novel predictor for better prognosis in 
NSCLC patients.
Introduction
Lung cancer is still the leading cause of cancer death in both 
sexes throughout the world. More people die of lung cancer 
than of colon, breast, and prostate cancers combined, i.e., 
more than 1.2 million deaths each year (1). Non-small cell 
lung cancer (NSCLC) accounts for approximately 85-90% 
of all lung cancers. The poor prognosis of NSCLC is mainly 
due to late diagnosis, in as much as only 20 to 30% of patients 
are eligible for surgical resection. Despite the development 
of new chemotherapeutic drugs and multimodal treatment 
strategies, the survival rate of NSCLC remains unchanged 
and poor. Identification of new prognostic markers for the 
characterization of lung-cancer biology may be helpful, as 
they could serve as a basis for predicting response to radia-
tion and chemotherapy at a molecular level.
The alterations in epigenomes such as DNA methylation 
and histone modifications play pivotal roles in carcinogenesis 
(2-4). It has been reported that DNA methylation level and 
global histone modification patterns may be possible predic-
tors of cancer recurrence and prognosis in a large variety of 
cancer entities (5,6). Post-translational modification of histone 
tails alters the physical state of chromatin and has an essential 
role in both transcriptional repression and activation during 
embryonic development, lineage specification, terminal differ-
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entiation and tumorigenesis as well (7,8). One such repressive 
modification, the trimethylation of lysine 27 on histone H3 
(H3K27me3), seemed to be an epigenetic label mediating 
gene silencing; and a mark for de novo DNA methylation 
in cancer cells by recruitment of DNA methyltransferase 
(DNMTs) (9-11), contributing to tumor progression through 
suppression of a certain gene expression (12). In fact, many 
recent studies have revealed that H3K27me3 may be involved 
in the characterization of various types of human cancers, 
including breast cancer (5,13), hepatocellular carcinoma (14), 
prostate cancer (15), Hodgekin's lymphoma (16), esophageal 
cancer (17) and nasopharyngeal carcinoma (18). Reports of 
H3K27me3 levels in different cancer samples are somewhat 
contradictory. It is demonstrated that low H3K27me3 levels 
predicted poor outcome in breast, ovarian and pancreatic 
cancers (5) while high levels predicted poor outcome in 
hepatocellular carcinoma (14) and esophageal squamous cell 
carcinoma (17).
Moreover, H3K27 methylation is catalyzed by the SET 
domain of its specific methyltransferase, enhancer of zeste 
homolog 2 (EZH2), and requires the presence of 2 additional 
proteins, i.e., suppressor of zeste 12 (SUZ12) and embry-
onic ectoderm development (EED) (19). These proteins, 
together with the histone binding proteins retinoblastoma 
binding protein 4 (RBBP4) and RBBP7, comprise the core 
components of the polycomb repressive complex 2 (PRC2). 
Overexpression of EZH2 was also found in a variety 
of cancers, including lung cancer (20,21), breast cancer 
(5,22-26), melanoma (27), colorectal (20) and pancreatic 
adenocarcinoma (28) and ovarian carcinoma (29), and turned 
out to be closely associated with high proliferation rate and 
aggressive tumor subgroups, resulting in worse clinical 
outcome thereafter. Although many reports on the role of 
H3K27me3 in carcinogenesis are available, its carcinogenic 
role in NSCLC and how it interacts with EZH2 and DNA 
methylation remain unclear.
In the present study, we investigated the prognostic value of 
immunostaining for H3K27me3 and its relationship with EZH2 
expression in NSCLC patients. We examined the correlation 
between these parameters and the level of DNA methylation at 
CCGG sites, detected by histo-endonuclease-linked detection 
of methylation sites of DNA (HELMET) (30). Since there had 
been several reports to indicate that H3K27me3 and EZH2 
were involved in the early stage of various cancers, we focused 
on stage Ⅰ NSCLCs in this study.
Materials and methods
Patients and tissue preparation. Five normal lung tissue and 
42 NSCLC patients (22 adenocarcinomas and 20 squamous 
cell carcinomas) with early-stage (stage Ⅰ) were included in 
our study. Patients underwent radical resection of primary 
tumor (lobectomy or pneumonectomy) and systematic lymph-
adenectomy at the First Department of Surgery, Nagasaki 
University Hospital (Nagasaki, Japan), between 2000 and 
2006. The patients' clinicopathological data are shown in 
Table I. None of the patients had received chemo- or radio-
therapy before tissue collection. The histopathologic features 
of the tumor specimens were classified in accordance with the 
WHO criteria. The TNM staging was determined according 
to the latest National Comprehensive Cancer Network 
(NCCN, Version 2, 2013) guidelines for NSCLC. The 
study protocol was approved by the Human Ethics Review 
Committee of Nagasaki University School of Medicine, and 
a signed informed consent was obtained from each patient. 
Each specimen was fixed overnight in 10% buffered formalin 
at room temperature (RT) and embedded in paraffin. Serial 
sections were cut at a thickness of 4 µm and placed onto 
3-aminopropyltriethoxysilane-coated glass slides. Some 
sections were stained with hematoxylin and eosin in a routine 
manner for histological examination.
Chemicals and biochemicals. Bovine serum albumin 
(BSA) (essentially fatty acid and globulin-free), Trizma 
base, 2-mercaptoethanol, 3-aminopropyltriethoxysilane, 
Triton X-100, and Brij-35 were from Sigma Chemical Co. 
(St. Louis, MO, USA). Sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis (PAGE) reagents and 
the molecular marker set were purchased from Daiichi Pure 
Chemicals (Tokyo, Japan). Polyvinylidene fluoride membrane 
(PVDF) was purchased from Millipore (MA, USA). Lima 
bean trypsin inhibitor was purchased from Worthington 
Biochemical (Lakewood, NJ, USA); the protein assay kit 
and Coomassie Brilliant Blue were purchased from Bio-Rad 
Laboratories (Hercules, CA, USA); and 3,3'-diaminobenzi-
dine-4HCl (DAB) was purchased from Dojin Chemical Co. 
(Kumamoto, Japan). Biotin-16-dUTP, digoxigenin-11-dUTP, 
Rhodamine anti-Dig and terminal deoxynucleotidyl trans-
ferase (TdT) were from Roche Diagnostics (Mannheim, 
Germany). Dideoxy ATP (ddATP) and dideoxy TTP (ddTTP) 
were from Jena Bioscience (Jena, Germany). HpaII and MspI 
were from Takara Bio Inc. (Shiga, Japan). 4',6-diamidino-2-
phenyl-indole, dihydrochloride (DAPI) was from Invitrogen 
Corporation (Carlsbad, CA, USA). Permount was from Fisher 
Scientific Inc. (Bridgewater, NJ, USA). All other reagents 
used in this study were from Wako Pure Chemicals (Osaka, 
Japan) and were of analytical grade.
Immunohistochemistry for H3K27me3, EZH2, PCNA 
and simultaneous localization of EZH2 and PCNA. 
Immunohistochemistry was performed with the indirect 
enzyme-labeled antibody method, as described previously 
(31-33). Antibodies used in IHC are listed in Table II. For 
detection of H3K27me3, EZH2 and PCNA, paraffin-embedded 
sections were deparaffinized with toluene and rehydrated 
in graded alcohols. After autoclaved for 15 min at 120˚C in 
10 mM citrate buffer (pH 6.0) for antigen retrieval, endogenous 
peroxidase was inactivated with 0.3% hydrogen peroxide in 
methanol for 15 min. The sections were then pre-incubated 
with 500 µg/ml normal goat IgG dissolved in 1% BSA in PBS 
(pH 7.4) for 1 h, reacted with primary antibodies for 16 h, 
washed with 0.075% Brij 35 in PBS, and then incubated with 
HRP-conjugated goat anti-rabbit IgG (H3K27me3/EZH2) or 
HRP-conjugated goat anti-mouse IgG (PCNA) in 1% BSA 
in PBS for 1 h. After washing with 0.075% Brij 35 in PBS, 
the sites of HRP were visualized with DAB and H2O2 in 
the presence of nickel and cobalt ions (34). As a negative 
control, some sections were reacted with normal rabbit IgG 
or normal mouse IgG instead of the specific antibodies. For 
simultaneous staining of EZH2 and PCNA, the sections were 
INTERNATIONAL JOURNAL OF ONCOLOGY  43:  1467-1480,  2013 1469
incubated with Alexa 546 anti-rabbit IgG and Alexa 488 anti-
mouse IgG (both 1:500) in darkness for 1 h, then washed with 
0.075% Brij 35 in PBS in darkness and finally observed with 
0.5 µg/ml DAPI for 1 min. The stained slides were analyzed 
under a laser scanning microscope (LSM 5 PASCAL; Carl 
Zeiss Inc., Germany).
Quantitative evaluation. Staining results were examined 
by two observers masked to patients' clinical information. 
Another reading by a third observer was needed to reach a 
consensus when there was a significant discrepancy between 
initial readings. At least 5 high-power fields and more than 
2,000 cells were calculated in each case with a light micro-
scope (Zeiss 2021-85; Carl Zeiss Inc.) at x400 magnification. 
Immunostaining results were evaluated by using a semi-quan-
titative scoring system according to the method described in 
the study by Ellinger et al (15). That is, the number of positive 
cancerous cells was estimated as follows (0, no positive cells; 
1, 0> and ≤25% positive cells; 2, >25 and ≤50% positive cells; 
3, >50 and ≤75% positive cells; and 4, >75 and ≤100% positive 
cells). These scores were multiplied with an intensity scale (0, 
negative; 1, weak; 2, moderate; and 3, intensive), and the final 
score ranged from 0-12.
Western blot analysis of H3K27me3. Western blot analysis 
was carried out as detailed previously (35). In brief, human 
lung cancer specimens and normal lung tissue were homoge-
nized, and the lysates were centrifuged. Soluble proteins were 
separated on 10% SDS-PAGE gel (Daiichi Pure Chemical, 
Tokyo, Japan) with equal amounts (10 µg) of protein per lane. 
Separated proteins were electrophoretically transferred onto 
polyvinylidene difluoride (PVDF) membranes (Millipore), 
blocked with 10% non-fat milk in TBS (20 mM Tris buffer, 
pH 7.6, and 150 mM NaCl) for 1 h and then incubated over-
night at 4˚C with rabbit polyclonal anti-H3 (Cell Signaling 
Technology, MA, USA) and H3K27me3 antibody. As a 
secondary antibody, HRP-goat anti-rabbit IgG was reacted 
for 1 h and then the bands were visualized with DAB, Ni, Co 
and H2O2.
In situ evaluation of DNA methylation. To evaluate the DNA 
methylation level of pathological slides of NSCLC at CCGG 
sites, histo-endonuclease-linked detection of methylation sites 
of DNA (HELMET) was performed (30). Paraffin sections 
were dewaxed and digested with 10 µg/ml of proteinase K in 
PBS at 37˚C for 15 min. Then the sections were incubated 
with TdT buffer (25 mM Tris-HCl buffer, pH 6.6, containing 
0.2 M potassium cacodylate and 0.25 mg/ml BSA) alone at 
RT for 30 min. After incubation, the slides were reacted with 
800 U/ml of TdT dissolved in TdT buffer containing 20 µM 
ddATP, 20 µM ddTTP, 1.5 mM CoCl2 and 0.1 mM dithioth-
reitol at 37˚C for 2 h. After washing with PBS, the sections 
were fixed with freshly-prepared 4% PFA in PBS for 5 min 
and then rinsed with PBS. The non-methylated CCGG sites 
were digested at 37˚C for 2 h by 100 U/ml HpaII dissolved in 
10 mM Tris-HCl buffer (pH 7.5), containing 10 mM MgCl2 
and 1 mM dithiothreitol. The HpaII-cut sites were labeled 
with biotin-16-dUTP by TdT reaction for 90 min. Then, the 
3'-OH ends were blocked with a mixture of dideoxynucleo-
tides by TdT, as described above, for 2 h. After fixation with 
4% PFA in PBS, the methylated CCGG sites were digested at 
37˚C for 2 h by 100 U/ml MspI dissolved in Tris-HCl buffer 
(pH 7.9), containing 10 mM MgCl2, 0.5 mM dithiothreitol, 
Table I. Clinicopathologic parameters.
 No. of cases (%)
 ---------------------------------------------------------------
 Adeno- Squamous
Parameters carcinoma cell carcinoma
Median age, years 68.50 69.75
Age (y.o.)
  ≤69 12 (54.5) 12 (60)
  >69 10 (45.5)   8 (40)
Gender
  Male 10 (45.5) 17 (85)
  Female 12 (54.5)   3 (15)
Serum CEA (ng/ml)
  ≤5 22 (100) 17 (85)
  >5   0    3 (15)
P-factor
  Positive   1 (4.5)   0
  Negative 21 (95.5) 20 (100)
LV-factor
  Positive 18 (81.8) 13 (65)
  Negative   4 (18.2)   7 (35)
V-factor
  Positive   8 (36.4) 10 (50)
  Negative 14 (63.6) 10 (50)
T-stage
  1a 16 (72.7) 13 (65)
  1b   5 (22.7)   7 (35)
  2a   1 (4.6)
Nodal status
  N0 22 (100) 20 (100)
Differentiation
  Well 13 (59.1)   3 (15)
  Moderate   6 (27.3)   9 (45)
  Poor   3 (13.6)   8 (40)
Relapse
  Yes   2 (9.1)   8 (40)
  No 20 (90.9) 12 (60)
Smoking status
  Smoker   7 (31.8) 17 (85)
  Non-smoker 15 (68.2)   3 (15)
Postoperative metastasis
  Yes   3 (13.6)   7 (35)
  No 19 (86.4) 13 (65)
Median follow-up (months) 75.2 52.9
CEA, carcinoembryonic antigen; P-factor/LV-factor/V-factor, the 
status of tumor invasion into visceral pleura (P)/lymphatic ves-
sels (LV)/veins (V).
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66 mM potassium acetate, and 0.1% BSA. The MspI-cut 
sites were then labeled with digoxigenin-11-dUTP by TdT 
reaction for 90 min. Finally, the sections were incubated 
with a mixture of 500 µg/ml normal goat IgG and normal 
sheep IgG in 5% BSA/PBS for 1 h, and then visualized by 
FITC-labeled goat anti-biotin and rhodamine-labeled sheep 
anti-digoxigenin. The nuclei were stained with 0.5 µg/ml 
DAPI for 1 min.
Statistical analysis. The X-tile software program (Version 
3.6.1; Yale University School of Medicine, New Haven, CT, 
USA) as described previously (36) was used to determine the 
best threshold value of H3K27me3 for classifying samples 
into groups of high and low expression. The SPSS 18.0 statis-
tical software package (SPSS Inc, Chicago, IL, USA) was 
employed for all analyses. The association between tested 
markers and different clinicopathological characteristics of 
the patients, including age, gender, tissue type, tumor differen-
tiation, P-factor, LV-factor, V-factor, smoking status, relapse, 
postoperative metastasis and CEA level were evaluated by 
Pearson's χ2 or Fisher's exact test as appropriate. The Kaplan-
Meier method with log-rank test was used for estimating 
probability of overall survival. The Cox proportional hazard 
model was used to evaluate the association between various 
markers and patient's survival. Univariate and multivariate 
analyses were determined by Cox regression. A p-value <0.05 
was considered statistically significant.
Results
Clinicopathological data of patients. As shown in Table I, 
the diagnosis of the 5 normal lung specimens was identically 
pneumothorax. Three females and 2 males were included, with 
an average age of 67.6 years. The cancer patient population 
included 27 males and 15 females and had a mean age of 69 
years. By histological classification, 20 cases were squamous 
cell carcinoma and 22 were adenocarcinoma. Of the 22 cases 
of adenocarcinoma, 13 patients had well-differentiated 
tumor, 6 had moderately- and 3 had poorly-differentiated 
tumor. In the 20 cases of squamous cell carcinoma, the well-, 
moderately- and poorly-differentiated numbers were 3, 9 and 
8, respectively. All cases were TNM stage Ⅰ and lymph node 
negative. Postoperative follow-up data were available in all 
cases, and the median follow-up duration in adenocarcinoma 
and squamous cell carcinoma groups were 75.2 months and 
52.9 months, respectively.
Trimethylation level of histone H3 at lysine 27 in normal 
lung and NSCLC tissues. Either in normal lung or NSCLC 
tissues, H3K27me3 was localized predominantly in the nuclei 
(Fig. 1). Specificity of the antibody for H3K27me3 was deter-
mined by western blot analysis (Fig. 2H). Calculated staining 
score of immunopositive cells ranged from 0 to 12 in all tested 
tissues. According to the X-tile plots (Fig. 2D-F), we catego-
rized the samples into low (IHC score ≤3) and high (IHC 
score >3) expression subgroups based on a cut-point deter-
mined by X-tile software related to survival status ((Fig. 2F, 
P<0.05). As shown in Fig. 2A, high expression of H3K27me3 
was observed in all 5 (100%) normal lung tissues, whereas in 
cancer tissues, high methylation level of H3K27 was found 
in 18 (81.8%) adenocarcinomas and 6 (30%) squamous cell 
carcinomas (P<0.01). The staining score of H3K27me3 was 
significantly higher in normal lung tissue compared to those 
of adenocarcinoma and squamous cell carcinoma (11.2±0.8, 
7.55±0.77 and 3.55±0.61, respectively, P<0.05, Figs. 1 and 2A). 
In addition, a positive relationship between tumor differen-
tiation and H3K27me3 expression was found (Figs. 1, 2B and 
C). In both cancer subtypes, higher positive staining score 
was correlated with better cellular differentiation (P<0.01). 
In the adenocarcinoma subgroup, staining scores for well-, 
moderately- and poorly-differentiated NSCLC samples were 
8.69±1.00, 7.00±1.24 and 3.67±1.20, respectively (P<0.01). In 
the squamous cell carcinoma subgroup, their staining scores 
were 8.00, 2.78±0.70 and 2.75±0.82, respectively (P<0.01).
Correlation of H3K27me3 expression with clinicopatholog-
ical parameters. To determine the correlation of H3K27me3 
expression and clinicopathological parameters, and to 
determine its prognostic impact, χ2 analyses together with 
univariate, multivariate and Kaplan-Meier survival analyses 
of cumulative survival analysis were performed. Correlation 
analyses (Table III) revealed that H3K27me3 expression was 
significantly associated with non-SCC histology (P=0.001), 
better cellular differentiation (P=0.002), non-smoking status 
(P=0.019), low EZH2 expression (P=0.038), high meth-
ylation level at CCGG sites (P=0.049) and tumor-specific 
survival after resection of primary tumors (P<0.01 by log-
rank test, Fig. 2G). Kaplan-Meier survival analysis revealed 
Table II. List of antibodies used in immunohistochemistry.
 Working
Antibody dilution/concentration Manufacturer
Polyclonal, rabbit anti-human H3K27me3 1:200 Cell Signaling Technology, MA, USA
Monoclonal, rabbit anti-human EZH2 1:400 Cell Signaling Technology
Monoclonal, mouse anti-human PCNA (clone: PC10) 1:400 DakoCytomation, Glostrup, Denmark
HRP-conjugated goat anti-rabbit/mouse IgG 1:200 Millipore Co., CA, USA
Normal goat IgG 1:20 Sigma Chemical Co., MO, USA
Alexa 488 anti-mouse/Alexa546 anti-rabbit 1:500 Invitrogen Co., CA, USA
FITC-labeled goat anti-biotin 1:100 Vector Laboratories, CA, USA
Rhodamine-labeled sheep anti-digoxigenin 1:100 Roche Diagnostics, Mannheim, Germany
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Figure 1. Immunohistochemical staining for H3K27me3 in different lung tissues and its relationship with overall survival. (A) Strong expression of H3K27me3 
in normal lung tissue; (B) negative control; scale bar, 20 μm. (C, E and G) H3K27me3 expression varied obviously in well, moderate and poor differentiation of 
squamous cell carcinoma. (D, F and H) H3K27me3 expression varied obviously in well, moderate and poor differentiation of adenocarcinoma, which decreased 
as differentiation level reduced.
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Figure 2. (A) H3K27me3 expression differed in different lung tissues, *P<0.05 and **P<0.01 compared to normal lung; error bars, SD of mean. (B) In ADE, 
H3K27me3 expression reduced markedly as differentiation decreased, *P<0.05 compared to poor differentiation. (C) In SCC, H3K27me3 expression reduced 
markedly as differentiation decreased, **P<0.01 compared to moderate or poor differentiation. (D) X-tile plots of H3K27me3 expression for optimal cut-point 
(3, P<0.05), which is demarcated by the circle (black with white border). (E) The cut-point was used to separate low H3K27me3 expression (blue) from high 
H3K27me3 expression (gray) in the expression frequency histogram of the whole sample set. (F) Kaplan-Meier curve for testing the survival of sample subsets 
defined by H3K27me3 expression below 3 (green line) and above 3 (gray line). (G) Kaplan-Meier curves of OS in different levels of H3K27me3 expression in 
NSCLC patients. High expression of H3K27me3 (green line) was associated with better prognostic outcome and longer disease-free survival time while low 
expression of H3K27me3 (red line) with worse prognosis and shorter DFS/OS, P<0.05. (H) To determine the specificity of H3K27me3 antibody, western blot 
analysis (10 µg protein/lane) were performed to detect H3K27me3 expression in both normal lung tissue (upper left panel) and lung adenocarcinoma (upper right 
panel, well differentiation), and histone H3 expression was used as internal control (lower panel).
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Table III. Association of  H3K27me3, EZH2 expression and DNA methylation level at CCGG sites with clinicopathologic parameters 
in NSCLC patients.
 H3K27me3 EZH2 DNA methylation
 -------------------------------------------------------------- ------------------------------------------------------------------ ---------------------------------------------------------------
 All    All    All
Variables cases H L P-value cases H L P-value cases H L P-value
Agea (y.o.)    0.857    0.653    0.245
  ≤69 18 10   8  18   7 11  24   9 15
  >69 24 14 10  24 11 13  18 10   8
Gender    0.114    0.026    0.152
  Male 27 13 14  27 15 12  27 10 17
  Female 15 11   4  15   3 12  15   9   6
Tissue type    0.001    0.000    0.059
  ADE 22 18   4  22   3 19  22 13   9
  SCC 20   6 14  20 15   5  20   6 14
Differentiation    0.002    0.067    0.261
  Well 16 14   2  16   4 12  16   9   7
  Moderate/poor 26 10 16  26 14 12  26 10 16
P-factorb    1.000    1.000    0.452
  Yes   1   1   0    1   0   1    1   1   0
  No 41 23 18  41 18 23  41 18 23
LV-factorb    1.000    1.000    0.180
  Yes 31 18 13  31 13 18  31 12 19
  No 11   6   5  11   5   6  11   7   4
V-factor    0.150    0.038    0.049
  Yes 18   8 10  18 11   7  18   5 13
  No 24 16   8  24   7 17  24 14 10
Smoking status    0.019    0.019    0.016
  Smoker 24 10 14  24 14 10  24   7 17
  Non-smoker 18 14   4  18   4 14  18 12   6
Relapseb    0.010    0.720    1.000
  Yes 10   2   8  10   5   5  10   4   6
  No 32 22 10  32 13 19  32 15 17
Postoperative metastasisb    0.281    0.281    0.305
  Yes 10   4   6  10   6   4  10   3   7
  No 32 20 12  22 12 20  32 16 16
CEAb (ng/ml)    0.567    0.071    0.239
  ≤5 39 23 16  39 15 24  39 19 20
  >5   3   1   2    3   3   0    3   0   3
EZH2c    0.038        0.049
  ≤3.7 24 17   7      24 14 10
  >3.7 18   7 11      18   5 13
H3K27me3d        0.038    0.049
  ≤3     18 11   7  18   5 13
  >3     24   7 17  24 14 10
DNA methylationc    0.049    0.049
  ≤2.64 23 10 13  23 13 10
  >2.64 19 14   5  19   5 14
PCNAb    0.214    0.029    0.384
  ≤10%   6   5   1    6   0   6    6   4   2
  >10% 36 19 17  36 18 18  36 15 21
H, high expression/high CCGG sites methylation; L, low expression/low CCGG sites methylation; ADE, adenocarcinoma; SCC, squamous cell 
carcinoma; CEA, carcinoembryonic antigen; PCNA, proliferating cell nulear antigen; amean age; bFisher's exact tests (two-sided); χ2 test for all the 
other analyses; cmean score/ratio; dcut-point determined by X-tile software.
CHEN et al:  ASSOCIATION BETWEEN H3K27me3 EXPRESSION AND PROGNOSIS OF NSCLC1474
that patients with higher H3K27me3 expression in tumors 
showed longer disease-free survival in contrast to those with 
low expression. Univariate analysis revealed associations 
between poor prognosis in NSCLC patients and several 
factors, including low H3K27me3 expression (P=0.002), 
histologic type (non-ADE, P=0.011), smoking status (smoker, 
P=0.002), relapse (P<0.01), and postoperative metastasis 
(P<0.01, Table IV). Using a Cox proportional hazard regres-
sion analysis, we found that expression of H3K27me together 
with postoperative metastasis were independent predictors 
associated with prognostic outcome (Table IV).
Expression of EZH2 in lung tissues and its correlation with 
clinicopathological parameters. As shown in Fig. 3 (right 
panel), EZH2 was localized predominantly in nuclei, although 
occasionally it could be seen in the cytoplasm as background. 
In contrast with H3K27me3, no EZH2 staining was found in 
any of the 5 normal lung samples, and the staining for EZH2 in 
SCC was generally more intense than that of ADE (5.40±0.71 
vs. 2.18±0.54, P<0.01, Fig. 3B, D, F and G). Of 22 adenocarci-
nomas, 3 cases (13.6%) were defined as high expression. While 
in squamous cell carcinoma group, 15 out of 20 cases (75%) 
were considered as high expression (Fig. 3G). χ2 analyses 
demonstrated that when related to clinicopathological data 
(Table III), expression of EZH2 in NSCLC patients was found 
to be significantly associated with male gender (P=0.026), 
non-ADE histology (P<0.01), smoking status (P=0.019), low 
H3K27me3 expression (P=0.038), invasion into veins (V-factor, 
P=0.038), low methylation level at CCGG sites (P=0.049) and 
high PCNA percentage (P=0.029). It should be noted that 
the expression of EZH2 was correlated with lower level of 
H3K27 methylation while with enhanced PCNA expression, 
indicating its positive correlation with cell proliferating 
activity (Table III, Figs. 3A-F and 4). The reciprocal expres-
sion pattern of EZH2 and H3K27me3 in NSCLC was also 
confirmed immunohistochemically in mirror sections. As 
shown in Fig. 5, in lung adenocarcinoma (upper panel), the 
cells heavily stained for H3K27me3 were essentially negative 
or weak for EZH2 staining. In lung squamous cell carcinoma 
(lower panel), the expression of H3K27me3 seemed gener-
ally weaker than that of adenocarcinoma, however, identical 
cells with negative or weak staining of H3K27me3 were 
found with high level expression of EZH2. Both correlation 
analysis (Table III) and immunofluorescence double staining 
for EZH2 and PCNA (Fig. 4) confirmed that PCNA index 
was positively correlated with EZH2 expression. In contrast, 
neither univariate nor multivariate analysis indicated that 
EZH2 was an independent prognostic factor for surgically 
treated NSCLC patients enrolled in this study (P=0.720).
DNA methylation level at CCGG sites and its relation with 
clinicopathological parameters. As shown in Figs. 6 and 7, 
CCGG sites in cancer cells were generally hypermethyl-
ated, compared to that of normal cells. Although no 
correlation was found between DNA methylation level 
at CCGG sites and DFS/OS, we found that higher DNA 
methylation level at CCGG sites in NSCLC patients was 
significantly associated with less pulmonary vein invasion 
(V-factor, P=0.049), non-smoking status (P=0.016), low 
EZH2 expression (P=0.049) and high H3K27me3 expres-
sion (P=0.049) (Table III). Although the expression of 
H3K27me3 was correlated with differentiation status, and 
DNA methylation level at CCGG sites was correlated with 
the methylation level of H3K27 positively, no correlation 
between DNA methylation and differentiation level was 
found (P=0.261).
Table IV. Univariate and multivariate analyses of factors associated with OS.
Variables Hazard ratio (95% confidential interval, CI) P-value
Univariate analysis
  Age (≤69 vs. >69) 1.248 (0.480-3.249) 0.649
  Gender (male vs. female) 0.461 (0.161-1.319) 0.149
  Tissue type (ADE vs. SCC) 0.276 (0.102-0.744) 0.011
  Differentiation (well vs. moderate/poor) 0.338 (0.109-1.048) 0.060
  P-factor (yes vs. no) 21.193 (0.000-1.031E7) 0.648
  LV-factor (yes vs. no) 0.921 (0.323-2.622) 0.877
  V-factor (yes vs. no) 0.573 (0.227-1.448) 0.239
  Smoking status (smoker vs. non-smoker) 0.131 (0.036-0.472) 0.002
  Relapse (yes vs. no) 0.134 (0.050-0.359) 0.000
  Postoperative metastasis (yes vs. no) 0.115 (0.041-0.322) 0.000
  Serum CEA level (ng/ml) (≤5 vs. >5) 0.043 (0.000-174.939) 0.458
  H3K27me3 (high vs. low) 0.187 (0.066-0.531) 0.002
  EZH2 (high vs. low) 1.975 (0.775-5.031) 0.154
  DNA methylation (high vs. low) 0.441 (0.165-1.176) 0.102
  PCNA (high vs. low) 0.755 (0.286-1.991) 0.569
Multivariate analysis
  Postoperative metastasis (yes vs. no) 0.115 (0.041-0.322) 0.000
  H3K27me3 (high vs. low) 0.205 (0.068-0.614) 0.005
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Figure 3. Correlation of expressions of EZH2 and PCNA in different lung tissues. Expression patterns of (A) PCNA and (B) EZH2 in normal lung (upper 
panel), adenocarcinoma (C and D, middle panel) and squamous cell carcinoma (E and F, lower panel) detected by IHC. Expression of PCNA was collateral 
with that of EZH2 in NSCLC tissues; scale bar, 20 µm. (G) Expression of EZH2 differed in different lung tissues; **P<0.01 compared to normal lung and ADE; 
error bars, SD of mean.
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Discussion
In the present study, we investigated the prognostic value 
of H3K27me3 and EZH2 expression in human lung cancer 
immunohistochemically, and found that, in comparison to 
normal lung tissue, the level of H3K27me3 was significantly 
downregulated in both ADE and SCC tissues of early-staged 
NSCLC. Furthermore, in each cancer subtype, the level of 
H3K27me3 was antiparallel with the cellular differentia-
tion level, and the decrease in H3K27me3 was significantly 
correlated with tumor relapse and shorter overall survival, 
strongly demonstrating that the level of H3K27me3 is a new 
epigenetic marker in lung cancers. In contrast, although 
EZH2 is known to catalyze trimethylation of H3K27, the 
expression of EZH2 in it was not significantly correlated with 
lung carcinogenesis.
Figure 4. Immunofluorescence double staining for EZH2 (rhodamine) and PCNA (FITC) in adenocarcinoma (left panel) and squamous cell carcinoma (right panel). 
Highlighted dotted area indicates that cancerous cells with high expression of EZH2 also exhibit high expression of PCNA, demonstrating their high level of cellular 
proliferation. Scale bar, 20 µm.
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With regard to the prognostic impact of H3K27me3 in 
various human cancers, it was reported that overexpression 
of H3K27me3 was linked to more malignant behavior and 
worse prognosis in patients with prostate (15), esophageal 
(17), nasopharyngeal (18) and hepatocellular carcinomas 
(14). On the other hand, in breast, ovarian and pancreatic 
cancers (5) and renal cell carcinoma (37), reduced expres-
sion of H3K27me3 was associated with worse prognosis. 
In human NSCLCs, however, we have found that a lower 
level of H3K27me3 was associated with higher tumor 
invasiveness and/or poorer disease-free survival (DFS) in 
this study. These contradictory findings may in part reflect 
that H3K27me3 marks different genes for silencing in 
different cell types. In the present study, we observed that 
low expression of H3K27me3 was a strong and independent 
predictor of poor cellular differentiation and shortened 
cancer-specific survival, as evidenced by univariate and 
multivariate analyses (Table IV). When the Cox regression 
model was constructed for the entire series, low H3K27me3 
expression remained an independent predictive factor of 
recurrence and/or cancer death in NSCLC patients. To our 
knowledge, our data presented here demonstrated for the 
first time a direct association of expression of H3K27me3 
with clinical outcome with NSCLCs. As H3K27me3 serves 
as an epigenetic mark mediating silencing and represses 
target gene expression, loss of it may result in reactivation of 
these silenced genes, such as some oncogenes, and therefore 
contributing to tumorigenesis or cancer progression.
EZH2 is involved in PRC2-directed gene silencing through 
the formation of H3K27me3 as an epigenetic marker. It was 
reported that EZH2 was found to be overexpressed at both 
mRNA and protein levels in NSCLC and bladder cancer, and 
correlated with invasiveness, increased proliferation and poor 
outcome (20,21). In colorectal cancer, EZH2 overexpression 
indicated a good prognosis, in contrast to the poor prognosis 
associated with EZH2 overexpression in NSCLCs (20). In the 
current study, we found that the higher expression of EZH2 
in NSCLC patients was significantly associated with various 
clinicopathological parameters including PCNA labeling 
index, which was consistent with the findings of Takawa et al 
(20), while we failed to confirm the significant correlation with 
poor prognosis (P=0.154). Further study with a greater number 
of specimens is needed.
In addition, we found that the expression of H3K27me3 was 
reversely correlated with that of EZH2 in NSCLC (Table III 
and Fig. 5). Similar findings have been recently reported by 
Holm et al (38) in breast cancer. Previous studies indicated that 
the polycomb group protein EZH2 directly methylated DNA 
in either normal (39) or cancerous (11) tissues, and might result 
in the inhibition of target gene expression through its meth-
ylation, also overexpression of EZH2 promoted formation of 
a different PRC complex, the PRC4, and exhibited differential 
Figure 5. Immunohistochemical staining for H3K27me3 (left panel) and EZH2 (right panel) in mirror sections of ADE (upper panel) and SCC (lower panel), 
demonstrating the reciprocal correlation between expression of H3K27me3 and EZH2. That is, NSCLC cells with high H3K27me3 expression exhibited low or 
negative expression of EZH2, and vice versa. Some cells with heavy staining of H3K27me3 are lymphocytes rather than cancer cells. The same type of arrows 
indicate the same cell type; scale bar, 20 µm.
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histone substrate specificities (40). Loss of H3K27me3 in tumor 
might reflect the formation of the new PRC complex to modify 
other histone residues. Since EZH2 methyltransferase activity 
requires its association with other PRC components, it has been 
proposed that overexpression of EZH2 may result in the disrup-
tion of the integrity of the PRC complexes or may form new 
PRC complexes (41,42), and thus the methyltransferase activity 
toward H3K27 may be changed.
It is clear that histone methylation marks do not act 
alone, but in a coordinated manner with other epigenetic 
modifications (4). DNA methylation principally occurs at 
cytosine residues located in dinucleotide CpG sites (43). 
CpG dinucleotides are statistically under-represented in the 
genome but are found to be concentrated in CG-rich regions 
termed CpG islands that frequently coincide with promoter or 
gene regulatory regions (3). Global hypomethylation appears 
to be an early event for colon and breast cancer as well as 
chronic lymphacytic leukemia (CLL) (44). In the present 
study, we evaluated the DNA methylation level at CCGG sites 
by means of HELMET, indicating that cancerous tissues were 
relatively hypermethylated in DNA at CCGG sites in contrast 
to that of normal lung tissue. This result is consistent with 
previous finding, that gene hypermethylation is an early event 
in the process of tumorigenesis of lung cancer (45). We also 
found that higher DNA methylation level at CCGG sites were 
statistically correlated with less chance of venous invasion, 
non-smoking status, lower expression of EZH2 and higher 
expression of H3K27me3 as well, although no significance 
of correlation with overall survival was found. This finding 
might still suggest that hypermethylation at CCGG sites 
contributes to better prognosis in NSCLC patients, because 
those factors were more or less affecting the outcome of 
NSCLC patients. On the other hand, Lin et al (46) have 
reported that hypermethylation in CpG was correlated with 
poor prognosis in NSCLC, contrary to our findings. Although 
the reason for this discrepancy is not known, the genes that 
were hypermethylated in the studies might be different. 
Since DNA methylation in cancer was mainly targeted to 
polycomb-regulated genes and a very high percentage of the 
methylated genes was pre-marked with trimethylated H3K27 
in addition to other polycomb components (10), further study 
is needed to clarify which gene is involved and whether or not 
methylation of H3K27 also plays a role in the interaction with 
this hypermethylation.
Some limitations of this research should be noted. First of 
all, the dataset was small and as a result the statistical power 
would be somewhat limited. Further study with larger number 
of samples is necessary to validate the present results. Although 
the number of specimens used here was limited, we did achieve 
some significant indications, showing that high expression of 
H3K27me3 was correlated with longer disease-free survival. 
Secondly, all the cases involved in this study were patients of 
TNM stage I. Although chemotherapy or radiotherapy would 
be used after progression had been proved, the contribution 
of other therapies to overall survival had not been taken into 
account in the survival analysis, for surgery was considered the 
key therapy for patients at this stage, and thus would probably 
lead to some bias.
In conclusion, our study indicated that high expression of 
H3K27me3 was associated with clinicopathological parameters 
Figure 6. Simultaneous localization of non-methylated and methylated CCGG 
sequences by HELMET in paraffin-embedded sections of normal lung. The 
paraffin-embedded section was blocked with a dideoxynucleotide mixture by 
TdT and then the Hpa II cutting sites were labeled with biotin-16-dUTP. After 
dideoxynucleotide blockade, Msp I cutting sites were labeled with digoxi-
genin-11-dUTP and both haptens were visualized with (A) FITC anti-biotin 
and (B) rhodamine anti-digoxigenin, respectively. Merged images are shown 
in (C). In normal lung tissue, both non-methylated and methylated CCGG 
sequences were evenly distributed within the nuclei.
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and correlated with better outcome in NSCLC patients as well. 
Thus H3K27me3 can be used as a good marker, enabling us 
to predict the prognosis of NSCLC patients, and to carry out a 
more intensive follow-up according to H3K27me3 expression 
status in resected specimens.
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Figure 7. Simultaneous localization of non-methylated and methylated CCGG sequences by HELMET in paraffin-embedded sections of ADE (left panel) and 
SCC (right panel). In contrast to normal lung tissue, hypermethylation was observed in both cancer tissue types. Within two types of NSCLC, higher methylation 
ratio in adenocarcinoma (left panel) was observed while relatively lower methylation ratio was found in squamous cell carcinoma (right panel), scale bar, 20 µm.
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